Synergism of colistin and globular endolysins against multidrug-resistant gram-negative bacteria

被引:0
|
作者
Zhang, Pengfei [1 ]
Zeng, Ping [1 ]
Lai, Christopher K. C. [2 ]
Ip, Margaret [2 ]
To, Kenneth K. W. [1 ]
Zuo, Zhong [1 ]
Xia, Jiang [3 ]
Leung, Sharon S. Y. [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Chem, Hong Kong, Peoples R China
关键词
Endolysin; Colistin; Gram-negative bacteria; ACINETOBACTER-BAUMANNII; BIOFILM FORMATION; MECHANISMS;
D O I
10.1016/j.ijbiomac.2024.134670
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endolysins (lysins), a novel class of antibacterial agents derived from bacteriophages, efficiently lyse bacteria by degrading the peptidoglycan layer within the bacterial wall. Colistin, a classic peptide antibiotic with the ability to permeabilize the outer membrane, has recently shown great promise in synergizing with lysins against gramnegative bacteria. However, the exact mechanisms responsible for their synergy remain unclear. Here, we first demonstrated the synergistic bacterial killing of various lysin and colistin combinations. With a model lysin, LysAB2, we then confirmed that there is a threshold concentration of colistin causing sufficient permeabilization of the outer membrane for lysin to access the peptidoglycan layer and subsequently exert its lytic ability. The threshold colistin concentrations were found to range 0.2-0.8 mu M for the tested bacteria, with the exact value largely depending on the density of lipopolysaccharides on the outer membrane. Beyond the threshold colistin level, LysAB2 could synergize with colistin at a concentration as low as 0.31 mu M. Next, we proved for the first time that lysin-induced degradation of the peptidoglycan layer facilitated the disruption of cytoplasmic membrane by colistin, elevated the level of reactive oxygen species in bacterial cells, and boosted the killing effect of colistin. Additionally, the colistin-lysin combination could effectively eliminate established biofilms due to the biofilm dispersal ability of lysin. The in-vivo efficacy was preliminary confirmed in a Galleria mellonella infection model for combination with colistin doses (>= 1.8 mu g/larvae), which could reach beyond the threshold concentration, and a fixed LysAB2 dose (10 mu g/larvae). In summary, our study provided the first experimental evidence unravelling the mechanisms behind the synergy of colistin and lysins. All these findings provided important insights in guiding the dosing strategy for applying this combination in future development.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Multidrug-resistant (MDR) Gram-negative bacteria information leaflets
    Brown, C.
    Livermore, D. M.
    Otter, J. A.
    Warren, R. E.
    Jenks, P.
    Enoch, D. A.
    Newsholme, W.
    Oppenheim, B.
    Leanord, A.
    McNulty, C.
    Tanner, G.
    Bennett, S.
    Cann, M.
    Bostock, J.
    Collins, E.
    Peckitt, S.
    Ritchie, L.
    Fry, C.
    Hawkey, P.
    Wilson, A. P. R.
    JOURNAL OF HOSPITAL INFECTION, 2016, 92 (01) : 86 - 87
  • [32] The emerging threat of multidrug-resistant Gram-negative bacteria in urology
    Hosam M. Zowawi
    Patrick N. A. Harris
    Matthew J. Roberts
    Paul A. Tambyah
    Mark A. Schembri
    M. Diletta Pezzani
    Deborah A. Williamson
    David L. Paterson
    Nature Reviews Urology, 2015, 12 : 570 - 584
  • [33] Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria
    Tangden, Thomas
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2014, 119 (02) : 149 - 153
  • [34] The emerging threat of multidrug-resistant Gram-negative bacteria in urology
    Zowawi, Hosam M.
    Harris, Patrick N. A.
    Roberts, Matthew J.
    Tambyah, Paul A.
    Schembri, Mark A.
    Pezzani, M. Diletta
    Williamson, Deborah A.
    Paterson, David L.
    NATURE REVIEWS UROLOGY, 2015, 12 (10) : 570 - 584
  • [35] Intravenous colistin therapy for infections caused by multidrug-resistant gram-negative bacteria in critically ill patients
    Cusato, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E195 - E195
  • [36] Infection control measures against multidrug-resistant Gram-negative bacteria in children and neonates
    Karampatakis, Theodoros
    Tsergouli, Katerina
    Roilides, Emmanuel
    FUTURE MICROBIOLOGY, 2023, 18 (11) : 751 - 765
  • [37] In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
    Mushtaq, Shazad
    Sadouki, Zahra
    Vickers, Anna
    Livermore, David M.
    Woodford, Neil
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [38] New drugs against multidrug-resistant Gram-negative bacteria: a systematic review of patents
    Jimenez, Maria C.
    Kowalski, Layza
    Souto, Ricardo B.
    Alves, Izabel A.
    Viana, Max D. M.
    Aragon, Diana M.
    FUTURE MICROBIOLOGY, 2022, 17 (17) : 1393 - 1408
  • [39] Tetracycline improved the efficiency of other antimicrobials against Gram-negative multidrug-resistant bacteria
    Mawabo, Isabelle K.
    Noumedenn, Jaures A. K.
    Kuiate, Jules R.
    Kuete, Victor
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2015, 8 (03) : 226 - 233
  • [40] Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in Pediatric Patients
    Karaaslan, Ayse
    Cagan, Eren
    Kadayifci, Eda Kepenekli
    Atici, Serkan
    Akkoc, Gulsen
    Yakut, Nurhayat
    Demir, Sevliya Ocal
    Soysal, Ahmet
    Bakir, Mustafa
    BALKAN MEDICAL JOURNAL, 2016, 33 (06) : 627 - 632